Read the press release here.
Kalamazoo-based medical device startup C2Dx was founded by Kevin McLeod and Ann Arbor-based growth capital firm Plymouth Growth in 2019 to invest in and refine the delivery of “valuable niche products” to propel its growth.
And that’s exactly what happened in 2021.
C2Dx’s second product acquisition occurred early last year when it purchased Stryker’s T/Pump product line. T/Pump includes devices that provide localized temperature therapy for pain relief and patient comfort and often is used for orthopedic conditions, acute injuries, chronic pain and muscle strains, as well as skin trauma, burns, contusions and other localized pain diagnoses like arthritis and neuritis.
“The addition will provide great opportunity for growth for both C2Dx and the product itself,” McLeod said.
C2Dx’s first acquisition was the STIC Intra-Compartmental Pressure Monitor, a device that addresses “compartment syndrome,” which can lead to irreversible muscle and nerve damage, infection and potential amputation.
The T/Pump product line’s controlled warming and cooling temperature settings and multiple treatment cycle options allow therapy to be customized to each patient’s needs.
C2Dx is dedicated to growing resources, jobs and opportunities in West Michigan, and brought together previous Stryker executives, each with over 20 years in leadership, to launch its first product.
“Our leadership team has extensive experience leading all phases of medical device manufacturing,” McLeod said. “We have proven ourselves with a very successful initial product offering, and now we are excited to offer another valuable product and further pursue C2Dx’s mission.”
Posted by Clinical Publication Group in News, Press Releases
